GeneDx Q3 Revenue Posts 65% Growth to $116.7M with 74% Gross Margin
GeneDx posted Q3 2025 revenue of $116.7 million, a 65% year-over-year increase in exome/genome testing, with adjusted net income of $14.7 million and a 74% gross margin. It secured FDA Breakthrough Device status for ExomeDx and GenomeDx, conducting 25,700 tests and highlighting scale and payer adoption via proprietary interpretation IP.
1. Q3 Financial Results
GeneDx reported Q3 2025 revenue of $116.7 million, marking a 65% year-over-year increase in exome and genome testing. Adjusted net income reached $14.7 million, while gross margin expanded to 74%, reflecting improved profitability and operating leverage as testing volumes scaled.
2. Regulatory Milestones
The company obtained FDA Breakthrough Device designations for its ExomeDx and GenomeDx tests, accelerating payer engagement and potential coverage. These regulatory endorsements are expected to support broader commercial adoption and streamline reimbursement processes for rare-disease diagnostics.
3. Operational Scale and IP Moat
GeneDx conducted 25,700 exome and genome assays in Q3, representing 41% of total testing volumes year-to-date. Its proprietary variant database and clinical curation platform underpin a differentiated diagnostic yield and strengthen discussions with payers, creating a moderately durable moat.
4. Risks and Outlook
Key near-term risks include reimbursement delays, lab capacity constraints and potential operational disruptions that could impact volume-driven revenue. Positive catalysts include expanded commercial payer coverage, rising test volumes, continued margin expansion and publication of real-world evidence supporting clinical utility.